In addition, variance related to the donor state at time of phlebotomy, such as age, treatment status (whether donor was receiving IFN-β therapy or not), or disease subtype (relapsing remitting MS, secondary progressive MS or progressive relapsing MS) contributed each more than 5% to the overall variance. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.